戈舍瑞林对年轻乳腺癌患者化疗期间卵巢储备的保护作用:中国前瞻性队列研究
这项中国前瞻性队列研究纳入242例接受(新)辅助化疗的18-45岁I-III期乳腺癌患者,按意愿分为戈舍瑞林组和对照组,化疗后1年可评估149例。戈舍瑞林组AMH恢复率46.5%,对照组21.8%(OR 3.08,P=0.002),AFC和FSH恢复趋势一致;但41.3%月经恢复者AMH仍低。
要点
- 化疗同期使用戈舍瑞林与1年后AMH恢复率更高相关(46.5% vs 21.8%,OR 3.08,P=0.002)。
- AFC和FSH恢复率趋势与AMH恢复率一致。
- 41.3%月经恢复患者AMH水平仍低,月经恢复不能等同于卵巢储备恢复。
核心结论
- 与单纯化疗相比,化疗同期使用戈舍瑞林与化疗后1年卵巢储备恢复概率更高相关。
研究设计与样本
- 化疗后1年可评估149例,其中对照组76例、戈舍瑞林组73例。
主要发现
- 化疗后1年,戈舍瑞林组校正AMH恢复率为46.5%,对照组为21.8%(OR 3.08;P=0.002)。
- AFC和FSH恢复率趋势与AMH恢复率一致。
- 41.3%月经活动恢复的患者AMH水平仍低。
关键数值与推荐
- 戈舍瑞林组于首周期化疗前至少1周皮下注射3.6 mg,之后每4周一次直至化疗结束。
- 主要终点为AMH恢复率,次要终点为AFC、雌二醇(E2)、FSH和月经恢复率。
临床怎么用
- 对18-45岁、月经规律、需(新)辅助化疗的I-III期乳腺癌患者,可考虑化疗同期联用戈舍瑞林以保护卵巢储备。
- 评估卵巢储备恢复时不能仅依赖月经恢复,应结合AMH等指标。
局限性
- 因伦理考虑未随机分组,尽管采用倾向评分加权,选择偏倚仍不可避免。
- 21.5%(52/242)入组患者接受含GnRH激动剂的内分泌治疗,无法在化疗后1年和2年进行分析,研究把握度不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does goserelin, a GnRH agonist, have a protective effect in young breast cancer patients in terms of ovarian reserve markers anti-Müllerian hormone (AMH) and antral follicle count (AFC) during chemotherapy? SUMMARY ANSWER: Compared with chemotherapy alone, concurrent goserelin is associated with a higher probability of ovarian reserve recovery at 1 year after chemotherapy. WHAT IS KNOWN ALREADY: Previous studies on the administration of goserelin to protect ovarian function during chemotherapy have produced conflicting results because of the endpoint used, namely, chemotherapy-induced amenorrhoea. Reproductive medicine specialists consider AMH and AFC as the most sensitive ovarian reserve markers; however, they have never been used as biomarkers to assess the potential protective effects on ovarian reserve of goserelin during chemotherapy. STUDY DESIGN, SIZE, DURATION: This was a prospective cohort study in which patients were assigned to receive (neo)adjuvant chemotherapy with goserelin (the goserelin group) or without goserelin (the control group) according to each patient's preference. Of 242 breast cancer patients enrolled between December 2015 and November 2019, 76 in control group and 73 in goserelin group were able to be assessed at 1 year after chemotherapy. PARTICIPANTS/MATERIALS, SETTING, METHODS: Premenopausal patients with a regular menstrual cycle and aged 18-45 years were eligible for enrolment if they were newly diagnosed with stages I-III breast cancer for which treatment with adjuvant or neoadjuvant chemotherapy was planned. Each patient in the goserelin group was given a subcutaneous dose of 3.6 mg at least 1 week before the first cycle of chemotherapy and then every 4 weeks for the duration of chemotherapy. Ovarian reserve markers and menstrual status were evaluated before and after chemotherapy in the two treatment groups. The primary endpoint was the AMH recovery rate, the secondary endpoints were the recovery rates of AFC, estradiol (E2), follicle-stimulating hormone (FSH) and menstruation. MAIN RESULTS AND THE ROLE OF CHANCE: Among 149 patients (76 in the control group and 73 in the goserelin group) with complete data at 1 year after chemotherapy, the adjusted recovery rate of AMH was 46.5% and 21.8% in the goserelin group and control group, respectively (odds ratio: 3.08; P = 0.002). The trends in AFC and FSH recovery rates were consistent with that in AMH recovery rate. Notably, AMH levels remained low in 41.3% of patients whose menstrual activity had resumed. LIMITATIONS, REASONS FOR CAUTION: Randomisation was not performed because of ethical considerations, so selection bias was inevitable, although propensity score weighting was done. The study was also underpowered because 21.5% (52/242) of enrolled patients received GnRH agonist-containing endocrine therapy and could not be analysed at 1 and 2 years after chemotherapy. WIDER IMPLICATIONS OF THE FINDINGS: Our results indicate that co-administration of goserelin with chemotherapy provides obvious ovarian reserve protection in these young breast cancer patients. We expect that these results will be applicable in clinical practice for young breast cancer patients. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the National Key R&D Program of China No. 2016YFC0901302, by the Research and Development Fund of Peking University People's Hospital No. RD2014-13, RDY2017-19 and by AstraZeneca. The authors have no disclosures. TRIAL REGISTRATION NUMBER: NCT02430103.
引用
- Wang S, Pei L, Hu T, et al. Protective effect of goserelin on ovarian reserve during (neo)adjuvant chemotherapy in young breast cancer patients: a prospective cohort study in China. Hum Reprod. 2021. PMID: 33411897. doi:10.1093/humrep/deaa349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。